Wine with Heart combines the finer things in life: delectable food, the best local wines from the Santa Cruz mountains region, breathtaking views, a spirited live auction featuring one-of-a-kind items, and most importantly, a chance to donate generously to support the Fogarty Institute’s mission to advance medical innovation and drastically improve patient care.
Dr. Fogarty launches the Fogarty Institute for Innovation at El Camino Hospital; the first-of-its-kind nonprofit educational incubator.
The Institute hosts its first company-in-residence, HeartFlow, aimed at a noninvasive solution to accurately evaluate coronary heart disease, which is one of the leading causes of death in the U.S.
The Institute celebrates the graduation of its first startup, HeartFlow. The successful commercialization of its technology has greatly reduced healthcare costs and improved patients’ quality of life.
The Institute grows to nine companies-in-residence. Target areas include cardiovascular and venous disease.
Fogarty Institute adds 13,000 square feet of lab and office space to accommodate growing demand for its incubator program.
The Institute accepts seven new startups with expanded focuses, including surgical wound infections and women and infant health.
The Institute launches the Lefteroff Fund in honor of Tracy Lefteroff, with the mission of mentoring and educating young students who have an interest in life science innovation. To date, this hands-on program has hosted over 40 U.S. and international students.
The Institute welcomes its 20th startup, continuing its focus on developing companies that can transform healthcare.
Dr. Thomas Fogarty is awarded the Presidential National Medal of Technology and Innovation, the country’s highest honor for advancing science and technology.
The Fogarty Institute launches the first-of-its- kind educational fellowship program with the FDA, building deeper relationship between regulators and innovators. The program has grown fivefold since its inception.
nVision is the Institute's sixth company to successfully graduate, receiving Series B funding of $12 million. Its device shows compelling potential to revolutionize women’s healthcare.
The Institute launches the Ferolyn Fund with the mission of mentoring up-and-coming entrepreneurs who have a strong aptitude to transform healthcare. To date, three Fellows have successfully graduated from the program.
The Fogarty Institute names Andrew Cleeland as CEO, with the charge to expand on the organization’s vision and build upon the success of its 10-year track record.
Four new startups join the Institute’s incubator program targeting unmet healthcare needs that include non-healing wounds, hyperhidrosis and fetal health.
The 2017 Global Medical Device Industry Outlook found that funding, capital and regulatory challenges were among the top concerns for small companies. To address these challenges, the Institute has expanded our programs with the FDA.
The Institute held a first-of-its-kind half-day seminar and panel discussion with representatives from Longitude Capital, Lightstone Ventures, Silicon Valley Bank, Johnson & Johnson and Wilson Sonsini Goodrich & Rosati.
93% of startups admit that mentorship is pivotal to success, yet only 28% of small and medium businesses use mentors.* The Institute provides mentoring and educational workshops led by industry experts to help propel medical concepts from initiation to application.*The Sage Group plc
VC funding devoted to early-stage startups has gone from about 10% in the early 1990s to only 3% in recent years. The Institute is helping transform creative ideas into practical solutions that appeal to VCs, angel investors and established companies.
Research has shown that 70% of small businesses that receive mentoring survive for five or more years, double the rate of entrepreneurs who go at it alone.
Annually it costs the Institute approximately $100,000 for every company-in-residence we support. Thanks to our generous donors and corporate partners, we are able to support over 10 companies in any given year.
Dr. Fogarty helped launch the medical technology industry more than 50 years ago with the invention of the balloon catheter. This device transformed how surgery is performed today and has led to the development of multiple minimally invasive medical technologies that touch the lives of countless patients and their families.
Fifteen million Americans, or one in 50 people, suffer from hyperhidrosis, also known as excessive sweating. This little-talked-about condition can affect several locations on the body and dramatically affect quality of life in both social and professional settings.
palmm is developing a simple, at-home treatment for the condition, initially focusing on the hands, often cited as the most bothersome area and hardest to hide the condition. The startups’ technology gives an electrical stimulus to the skin which has proven to temporarily deactivate the sweat glands. The technology is incorporated into a glove, which still allows the user to conduct daily activities, such as typing or driving. The glove is worn once a week or every other week for about 30 minutes and its effect lasts an average of seven days. The glove is easy to use and painless.
Up to 60 million individuals in the U.S. suffer from debilitating gastrointestinal disorders. G-Tech Medical is developing a wearable technology aimed at improving outcomes and reducing costs by non-invasively monitoring gastrointestinal tract activity.
Led by CEO Steve Axelrod, PhD, G-Tech has launched clinical trials of its GutCheck System at El Camino Hospital. The pilot/feasibility study "Measurement of Gastrointestinal Myoelectric Activity in Patients At Risk For or Who Have a Post-Operative Ileus" uses the GutCheck System, comprised of a wireless, wearable, disposable patch and app to measure the electrical activity from the stomach, small intestine and colon. This electrical activity is a signal of motor activity of the organs, potentially a measure of their return to function after surgery. The two-year trial is expected to enroll 80 study participants at El Camino Hospital.
The treatment of severe, non-healing wounds resulting from trauma, diabetes, burns and surgery is on the rise due to an aging population and a rapid increase in diseases that cause chronic wounds. Experts have labeled acute wounds as a "public health and economic threat," affecting more than 110 million people worldwide and imposing a significant opportunity cost to stakeholders.
In developing countries, where resources are scarce and there is little to no access to high-quality healthcare, long-term hospital stays can be financially devastating for patients and their families who live on only a few dollars a day. Extended stays also cause a significant burden on already overcrowded hospitals.
Healyx, one of the Fogarty Institute's newest companies-in-residence, is set to meet this need by developing an innovative, cost-effective solution that improves upon negative pressure wound therapy (NPWT), a proven and leading method to treat chronic wounds. The simple device has the potential to save not only money… but also save limbs and lives.
Studies have found that nearly half of the C-sections performed in the U.S. were unnecessary, particularly for first-time mothers-to-be who were at low risk of needing a cesarean.
Many expecting mothers don't realize that C-sections can have serious short- and long-term implications, including post-partum depression, major complications from blood clots and injury to the bladder. Babies born via C-section are also at higher risk of suffering from long-term asthma and obesity and have a harder time breastfeeding.
Raydiant Oximetry is developing a device that non-invasively monitors a baby and mother's heart rate and oxygenation during labor with the aim to vastly reduce the number of unnecessary C-sections and improve outcomes.
EchoPixel, a startup that has developed a unique a medical visualization software platform, is undoubtedly one of the favorite stops when touring the Fogarty Institute.
Using 3D glasses and a special display, the company’s True 3D software system converts traditional CT images into interactive 3D renderings. With this system physicians can view and interact with anatomical structures as if they were real physical objects. The software offers an unprecedented way to examine patients' anatomy from every angle, making it easier to assess ailments and plan medical procedures.
EchoPixel’s software is being used in complex surgeries throughout the country, including a recent successful separation of conjoined twin sisters.
InterVene, a Fogarty Institute alumnus, has created a novel, minimally invasive device for the treatment of venous disease in the legs.
InterVene's technology represents the first non-implantable, catheter-based therapy to correct the underlying cause of chronic venous insufficiency (CVI). This condition is caused by improper function of the veins in the legs, which leads to blood pooling in the lower extremes, potentially causing skin changes and painful ulcerations. CVI afflicts approximately one quarter of adults and costs the U.S. healthcare system nearly $2 billion annually. To date, CVI treatment for patients with deep vein reflux is limited to compression stockings and wound care, or in rare cases, invasive surgery.
The company has moved into its new offices in South San Francisco, built its team to six members and added additional funding that helped develop a second-generation product, the BlueLeaf™ Endovenous Valve Formation System. The company is looking forward to gathering more clinical data in 2017 during an international extended feasibility study.
MedicalCue has developed a bedside tablet computer system that guides medical teams during newborn resuscitation. Much like a GPS offering real-time traffic avoidance, the startup's technology provides dynamic, real-time information needed during the complex steps of newborn resuscitation. The information provided to the delivery room staff is indexed to the national standard of care as developed by the American Academy of Pediatrics' Neonatal Resuscitation Program.
To make resuscitation easier, MedicalCue's system supplies both visual and audio information to clinicians. By automating routine tasks, such as record keeping and time keeping, this novel system also seeks to reduce the workload of nurses and doctors. Early testing of the system is demonstrating very promising results: In one study, the startup's device raised the accuracy of resuscitation delivery from approximately 55% to 95%.
MedicalCue is seeking to dramatically improve delivery room outcomes, considering that one in 10 babies globally need to be resuscitated at birth.
Zebra Medical Technology (ZTM) is creating the next generation of medical imaging that provides a non-invasive, real-time way to examine the skin and determine the potential presence of cancer. Over the past three decades, skin cancer has become the most prevalent type of cancer, outpacing all other types of cancer combined, including of the breast, lung and prostate.
Until today, cutting samples from the body for biopsy has been the only way to assess whether a new growth or lesion on the skin is cancerous. Of the 14.5 million biopsies conducted each year to determine the presence of skin cancer, nearly 76 percent reveal healthy tissue, creating an alarmingly high number of unneeded and costly procedures.
ZMT's patented handheld microscope, the EagleCyte, provides the immediate imaging features of an ultrasound, but with added cellular resolution and color contrast between cells and surrounding connective tissue that significantly improves pathology.
InPress Technologies, a Fogarty Institute graduate, has developed a simple device that is intended to quickly and effectively stop postpartum hemorrhage (PPH), the leading cause of maternal death globally, which takes the life of one woman every four minutes.
Nearly 80 percent of PPH cases are caused by uterine atony, or the failure of the uterus to contract to its correct postpartum size, which leaves intra-uterine blood vessels fully dilated. Women suffering from this condition are at risk of severe and dangerous blood loss that can lead to death.
Headed by Anne Morrissey as CEO and Jessie Becker as founder and COO, the startup has developed and patented the only device that treats uterine atony. Unlike other treatments available, its technology encourages the body’s natural response after childbirth by collapsing the uterus to its correct postpartum size to stop PPH.
InPress’ first-in-women clinical studies stopped postpartum hemorrhage within two minutes in all of its cases, without recurrence. The single-use device has the potential to dramatically reduce the cost of intervention during childbirth and substantially reduce the risk of loss of life, particularly in the developing world where the greatest incidence of maternal morbidity and mortality exist.
Materna is working to reduce the incidence of childbirth-related injuries and thereby the lifelong negative consequences women may experience due to such injuries. Approximately 11 percent of all women in the United States will undergo surgery to treat a pelvic floor disorder, and over one-third of all women currently suffer from symptoms. Materna’s first device prepares the pelvic soft tissues for delivery and has shown promise to prevent tears and pelvic muscle damage.
The company is currently preparing to launch its second device, Milli, which is aimed at treating pelvic pain, a condition that affects hundreds of thousands of women and often goes untreated. Materna originated from the Stanford Biodesign program.
nVision, a Fogarty Institute graduate, has long captured the interest of investors and healthcare professionals with its patented micro-catheter technology that allows unprecedented access to the fallopian tubes. The technology greatly expands diagnostic procedures that can be conducted in the gynecologist’s office, without painful incisions or general anesthesia, and allows detection of a host of clinical indications previously thought impossible.
Headed by founder, CEO and president Surbhi Sarna, the startup has developed two devices to aid clinicians in assessing tubal health: the first, Mako 7, allows physicians to access and collect cells from the fallopian tubes during a minimally invasive hysteroscopic procedure. The second device provides direct visualization of the fallopian tube lumen during hysteroscopy, which, when blocked, is one of the leading causes of infertility.
nVision has obtained FDA clearance for its first device, supported by a clinical study which demonstrated that 99 percent of the cell samples collected from the fallopian tube were adequate for further diagnostic evaluation.
First-in-women studies were successfully conducted for the second device and additional studies, followed by regulatory submissions, are planned.
Based in San Carlos, Calif., Prescient Surgical, a Fogarty Institute graduate, has developed a technology that holds the promise of reducing the incidence of surgical site infections (SSI).
Studies have shown that SSI adds $3 to 10 billion to the cost of healthcare each year in the U.S. alone. Between two and five percent of patients who undergo inpatient surgery will develop SSI, but those numbers increase significantly with higher-risk abdominal surgeries such as colorectal surgery, where infection rates commonly exceed 20 percent and result in higher treatment costs and longer hospital stays.
Prescient is expecting to receive 510(k) clearance shortly and is finishing development of an entire suite of products that target areas of acute need, including abdominal and laparoscopic surgeries, with pending expansion into vascular, orthopedic and endocrine surgeries.
The startup will initially focus on the U.S. market, followed by Europe and other continents as they continue to field interest from around the world.
Take the hottest tickets in town and combine them with pre-show dinner with cast members at a private in-theater meet-and-greet, two rear mezzanine show tickets and a signed cast poster. Lin-Manuel Miranda's "Hamilton: An American Musical" at San Francisco's Orpheum Theatre is an artistically electrifying and socially charged musical that will live in your mind long after the curtain falls.DONATED BY Santa Cruz Mountains Winegrowers
A San Jose Sharks Penthouse Executive Suite at the SAP Center for opening night against the Philadelphia Flyers. Package comes with 18 tickets, a private pre-game tour and a visit from a former San Jose Sharks player. Experiencing an exhilarating Sharks game from the penthouse suite is quite a treat. One of your group members can even ride the Zamboni during intermission!DONATED BY The San Jose Sharks
Enjoy a night of poker for 20 with professional dealers, catered dinner and drinks hosted by Andrew Cleeland at his house in Portola Valley. Grab 19 of your closest (or most competitive) friends and escape to a virtual Monte Carlo for a fun evening of friendly rivalry, gourmet cuisine and liberating libations. You never know who will show up!DONATED BY Andrew Cleeland
Eight magnums of wine from Santa Cruz Mountains Wineries! Enjoy the finest varietals this region produces. The Santa Cruz Mountains have been recognized as a premium wine-producing region since the late 1800s when local winegrowers first began to win acclaim for their wines in national and international competitions. This is a perfect way to explore these wonderful wines!DONATED BY Santa Cruz Mountains Winegrowers
One week in Casa San Francesco in Cortona. Casa San Francesco is a completely restored home located in upper Cortona with wonderful views of rooftops and the valley below, as well as San Francesco church. 3 bedrooms – sleeps 6 - Book a stay at Casa San Francesco, and enjoy in-home cooking classes with host Ivan for some of the best Tuscan food you will ever eat!DONATED BY Santa Cruz Mountains Winegrowers